GlaxoSmithKline has dropped plans to sell part of its HIV drugs unit and promised to hold its dividend steady for the next three years as the struggling UK pharmaceuticals group set out its strategy to revive growth.
葛兰素史克(GlaxoSmithKline，简称GSK)已放弃了转让部分艾滋病(HIV)药物部门的计划，并承诺要在今后三年内保证其稳定分红。这家深陷困境的英国制药集团正要着手实施其重获增长的战略。
您已阅读7%（314字），剩余93%（4516字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。